AMGN · AMGEN INC

461 filings

AMGN SEC Filings

AMGEN INC - 461 total filings

Filing record · 2016–202610-K1210-Q328-K125

Showing 1–50 of 461 filings

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2026

Amgen Inc. reported strong financial results for the second quarter and first half of 2026, with total revenues reaching $10.05 billion and $18.67 billion, respectively. This represents significant year-over-year growth, driven primarily by robust product sales, which increased by 9% in the quarter and 7% year-to-date. Net income also saw substantial increases, up 66% for the quarter to $2.38 billion and 33% year-to-date to $4.19 billion, leading to a diluted EPS of $4.37 and $7.71 for the respective periods. The company's balance sheet remains strong, with cash and cash equivalents growing to $13.99 billion. However, investors should note the ongoing significant U.S. tax dispute with the IRS, which could materially impact future financial results if an unfavorable outcome occurs. The company also faces continued pressure from biosimilar competition for certain key products like Prolia and XGEVA, which are impacting their sales.

Aug 5, 2026 8-K

AMGEN INC 8-K Report, Financial Results (Aug 4, 2026)

Amgen reported second-quarter 2026 results that beat on the top and bottom lines against the prior-year period. Total revenues rose 10% to $10.1 billion, with product sales up 9% to $9.5 billion driven mainly by volume. GAAP diluted EPS more than doubled... rising 65% to $4.37, largely because of lower acquisition-related amortization and a much smaller prior-year equity investment loss. Non-GAAP diluted EPS grew 4% to $6.29, held back by higher R&D (up 10%, led by MariTide Phase 3 spending), higher cost of sales from profit share and manufacturing, and a higher tax rate. Free cash flow was $3.5 billion versus $1.9 billion a year earlier, though the comparison is flattered by the final repatriation tax payment in Q2 2025. Growth is concentrated in newer products. Six key growth drivers rose 26% and represent nearly 70% of product sales, with strong gains from Repatha (+37%), EVENITY (+38%), TEZSPIRE (+42%), UPLIZNA (+90%), PAVBLU (+121%) and IMDELLTRA (+115%). Legacy franchises are under pressure from biosimilar and IRA-related pricing erosion: Prolia fell 32%, XGEVA fell 34%, Otezla fell 21%, and Enbrel fell 4% with net selling price down 22%. The company also faces a regulatory overhang on TAVNEOS, where the FDA has requested voluntary withdrawal and Amgen has requested a hearing, and it paused enrollment in two subcutaneous blinatumomab studies after an FDA partial clinical hold. Guidance was not changed in the excerpt provided: full-year 2026 non-GAAP EPS is $22.30 to $23.50, GAAP EPS is $15.80 to $17.08, and total revenues are expected at $38.2 to $39.4 billion. Balance sheet leverage increased, with debt rising to $57.3 billion from $54.6 billion at year-end 2025, and no share repurchases were made in the quarter. Investors will likely focus on the durability of the growth franchises, MariTide's Phase 3 progress, and the TAVNEOS regulatory outcome.

Aug 4, 2026 8-K

AMGEN INC 8-K Report, Cybersecurity Incident (Jul 31, 2026)

Amgen Inc. (AMGN) has disclosed a material cybersecurity incident identified in July 2026. The company detected unauthorized activity in its third-party cloud environments, which resulted in the exfiltration of various types of data, including proprietary information, patient protected health information, and other sensitive data. While Amgen has activated its response plan, engaged forensic experts, and is conducting an ongoing investigation, it has not yet identified any impact on its products, manufacturing operations, financial reporting, or its ability to serve patients. The company is actively assessing the full scope of the exfiltrated data and its potential implications. Despite the material nature of the incident, Amgen currently believes it is not reasonably likely to have a material impact on its financial condition or results of operations. Amgen is evaluating regulatory and legal notification requirements and will comply with all necessary disclosures, including to affected patients, as its investigation progresses.

Jul 31, 2026 8-K

AMGEN INC 8-K Report, Shareholder Vote Results (May 20, 2026)

Amgen Inc. (AMGN) has filed an 8-K Current Report detailing the outcomes of its recent annual meeting of stockholders held on May 19, 2026. The primary focus of the filing is the results of several key shareholder votes. Notably, all 12 director nominees were overwhelmingly elected to serve one-year terms, indicating strong shareholder confidence in the current board's leadership and governance. Furthermore, the company received shareholder approval for its executive compensation plan through an advisory vote, suggesting alignment between management's pay practices and investor expectations. The selection of Ernst & Young LLP as the independent registered public accountants for the fiscal year ending December 31, 2026, was also ratified, reinforcing the company's commitment to robust financial oversight. However, a shareholder proposal seeking to mandate an independent board chairman was not approved, indicating that the current structure of board leadership will remain in place.

May 20, 2026 8-K

AMGEN INC 8-K Report, Executive Changes (May 19, 2026)

Amgen (AMGN) announced in an 8-K filed May 19, 2026 that CFO Peter H. Griffith will retire from his Executive Vice President and Chief Financial Officer role effective August 31, 2026, after serving in the role since 2020. He will remain employed as a non-executive Executive Vice President through January 31, 2027 to support a transition, and he is retirement-eligible under company plans, so he will receive standard retirement benefits upon departure. Thomas Dittrich, 62, has been named his successor. He joins as a non-executive Executive Vice President on July 1, 2026 and becomes Executive Vice President and CFO effective September 1, 2026, reporting to Chairman and CEO Robert A. Bradway. He previously held senior finance roles at Amgen (including VP Finance and Chief Accounting Officer) and most recently served as CFO of Galderma Group AG, with prior CFO roles at Shire and Sulzer. His service at Galderma is expected to end June 30, 2026. Investors should note that the disclosed compensation package is substantial and front-loaded with make-whole awards designed to offset forfeited equity at his current employer. The transition appears planned and overlapping, with a two-month handover period and a retiring CFO available through January 2027, which reduces near-term execution risk. The filing does not indicate any change to Amgen's financial guidance, operations, or pipeline. The main items to monitor are Dittrich's relocation from Switzerland to California, the retention clawback terms, and whether the new CFO sets different capital allocation or reporting priorities.

May 19, 2026 10-Q

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2026

Amgen Inc. reported solid financial results for the first quarter of 2026, demonstrating growth in total revenues and net income compared to the prior year. Total revenues increased by 6% to $8.62 billion, driven by a 4% rise in product sales and a significant 45% surge in other revenues. Net income grew by 5% to $1.82 billion, resulting in diluted earnings per share of $3.34, up from $3.20 in the first quarter of 2025. The company experienced strong volume growth in key products such as Repatha, EVENITY, and TEPEZZA, while also seeing substantial increases in newer products like UPLIZNA and IMDELLTRA/IMDYLLTRA. Despite the positive top-line and bottom-line growth, investors should note the significant decline in sales for Prolia and XGEVA, which are facing increased biosimilar competition following patent expiries. Operating expenses decreased by 15%, largely due to the absence of a significant intangible asset impairment charge recorded in the prior year, and lower amortization expenses, which helped bolster profitability. However, ongoing litigation, particularly the significant U.S. tax dispute, remains a critical area to monitor, with a decision expected in the second half of 2026. The company also highlighted progress in its pipeline, including positive Phase 3 results for TEPEZZA administered subcutaneously.

May 1, 2026 8-K

AMGEN INC 8-K Report, Financial Results (Apr 30, 2026)

Amgen reported first quarter 2026 results that beat the prior-year period on the bottom line, with total revenues up 6% to $8.6 billion, GAAP EPS up 4% to $3.34, and non-GAAP EPS up 5% to $5.15. Product sales grew 4% to $8.2 billion, driven by 9% volume growth partially offset by 2% lower net selling price and 2% lower inventory. Sixteen products grew at least double digits, led by volume gains in Repatha, Uplizna, Imdelltra, Tepezza, and Tezspire. Profitability was strong: GAAP operating margin rose 17.4 points to 32.4%, largely because of lower acquisition-related amortization and a prior-year $800 million Otezla impairment, while non-GAAP operating margin edged down 0.4 points to 45.3%. Free cash flow rose to $1.5 billion from $1.0 billion, and debt climbed to $57.3 billion as cash reached $12.0 billion. The main risks are concentrated in legacy franchises and one regulatory matter. Prolia (down 34%), XGEVA (down 27%), and Enbrel (down 37%) face accelerating erosion from biosimilar competition and Medicare Part D price setting under the Inflation Reduction Act. The FDA has proposed withdrawing approval of TAVNEOS, citing questions about the evidence of effectiveness and the accuracy of ChemoCentryx's original application, and it also issued a Drug Safety Communication on fatal liver injury cases. Amgen says TAVNEOS will remain on the market during the review and that it intends to contest the proposal. Full-year 2026 guidance was reiterated with non-GAAP EPS of $21.70 to $23.10 and revenue of $37.1 billion to $38.5 billion, and the company is advancing a late-stage pipeline including MariTide Phase 3 obesity studies. For investors, the quarter shows underlying volume momentum in newer launches offsetting pricing and biosimilar pressure on the legacy base. The TAVNEOS regulatory process is the key near-term event to monitor, along with the pace of erosion in Prolia and XGEVA and execution on the MariTide program. No share repurchases were made in the quarter, and the dividend rose 6% to $2.52 per share.

Apr 30, 2026 8-K

AMGEN INC 8-K Report, Executive Changes (Apr 22, 2026)

Amgen (AMGN) announced in an 8-K filed April 22, 2026 that David M. Reese, Executive Vice President and Chief Technology Officer, will retire effective June 30, 2026. Dr. Reese, who joined Amgen in 2005 and previously led R&D from 2018 to 2023, remains an EVP until his retirement. The filing describes no financial results, guidance, or material financial impact; this is a leadership and organizational restructuring disclosure. The CTO responsibilities are being redistributed effective June 1, 2026: James E. Bradner takes on R&D, Artificial Intelligence and Data; Murdo Gordon becomes EVP of Amgen Global Markets and Policy; and CFO Peter H. Griffith absorbs part of the role. Sean Bruich is named SVP and Chief Technology Officer, and Paul Burton continues as SVP and Chief Medical Officer. Management frames the changes as a push toward "convergent innovation," integrating biology, data science and AI across discovery and commercial operations. For investors, the key takeaways are continuity and orderly succession rather than distress: the transition is pre-announced with a roughly two-month overlap, Dr. Reese is retirement-eligible and receives benefits under existing plans, and the restructuring consolidates technology strategy under R&D and commercial leadership. Investors should watch whether the AI and data agenda gains execution momentum under Bradner and Bruich, and whether the CFO's expanded remit affects financial oversight bandwidth. The filing itself does not quantify any cost or savings impact.

Apr 22, 2026 8-K

AMGEN INC 8-K Report, Material Agreement (Feb 19, 2026)

Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering completed on February 17, 2026. The company successfully issued and sold a total of $4.0 billion in senior notes across four tranches with varying maturity dates and interest rates. This offering includes $1 billion of 4.200% Senior Notes due 2031, $1.75 billion of 4.850% Senior Notes due 2036, $500 million of 5.500% Senior Notes due 2046, and $750 million of 5.650% Senior Notes due 2056. The net proceeds from this offering are approximately $3.96 billion, which will be used by the company for its general corporate purposes. The issuance of these notes, registered under an effective Form S-3, represents a strategic move to secure long-term funding. Investors should note that these senior notes rank equally with other existing and future senior unsecured indebtedness of Amgen. The terms include a provision for a change in control triggering event, where noteholders can require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest. This debt financing is a material event for Amgen, impacting its capital structure and future financial obligations.

Feb 19, 2026 10-K

AMGEN INC Annual Report, Year Ended Dec 31, 2025

Amgen's FY2025 10-K shows a company in transition: total revenues rose 10% to $36.8 billion, product sales grew 10% to $35.1 billion on 13% volume growth (offset by a 3% net price decline), and diluted EPS more than doubled to $14.23 from $7.56. Net income reached $7.7 billion, helped by $2.1 billion of unrealized equity gains (primarily the BeOne stake), a $1.2 billion Otezla intangible impairment, and lower amortization from the Horizon acquisition. Operating cash flow was $10.0 billion, with $1.9 billion of capex and $6.0 billion of debt retired, though stockholders' equity remains modest at $8.7 billion with an accumulated deficit. Growth is concentrated in newer launches: Repatha (+36%), TEZSPIRE (+52%), EVENITY (+34%), BLINCYTO (+28%), and IMDELLTRA. These offset steep erosion in ENBREL (-33%), driven by 340B mix, Medicare Part D redesign, and discounting, and an expected accelerated decline in Prolia and XGEVA as denosumab biosimilars launch after patent expiry. Policy headwinds are significant: IRA Medicare price setting begins with ENBREL in 2026 and Otezla in 2027, and MFN-related pricing commitments, state PDAB upper payment limits, and 340B expansion all pressure net pricing. Key risks include the IRS transfer-pricing dispute (about $3.6B and $5.1B in proposed federal tax plus penalties for 2010-2015, with a Tax Court decision not expected before H2 2026), the TAVNEOS FDA withdrawal request and Amgen's decision to contest it, the Regeneron antitrust verdict ($406.8M claimed), and the Otezla impairments. Management is investing heavily in R&D ($7.3 billion, up 22%), with six Phase 3 MariTide studies underway, and in U.S. manufacturing.

Feb 13, 2026 8-K

AMGEN INC 8-K Report, Financial Results (Feb 3, 2026)

Amgen reported fourth quarter and full year 2025 results that showed strong top-line momentum but a mixed quality-of-earnings picture. Full-year total revenues rose 10% to $36.8 billion, product sales grew 10% to $35.1 billion driven by 13% volume growth, and 14 products exceeded $1 billion in annual sales. GAAP EPS rose 88% to $14.23, though this was flattered by $2.0 billion of net gains on the BeOne equity investment and was partially offset by a $1.2 billion Otezla intangible asset impairment tied to IRA Medicare price setting. Non-GAAP EPS rose 10% to $21.84, and non-GAAP operating margin remained high at 46.1%, though it declined 0.8 points. Fourth-quarter results were weaker on cash and pricing. Q4 revenue grew 9% to $9.9 billion, but net selling price fell 4% and non-GAAP EPS was essentially flat at $5.29 as operating expenses rose 16%, driven by R&D up 26% on MariTide and business development. Free cash flow was $1.0 billion in Q4 versus $4.4 billion a year earlier, and $8.1 billion for the full year versus $10.4 billion, largely due to working capital timing. Debt fell to $54.6 billion, a 3.2x leverage ratio, and no shares were repurchased during 2025. The outlook is mixed. 2026 guidance calls for revenue of $37.0 to $38.4 billion, non-GAAP EPS of $21.60 to $23.00, and capex of about $2.6 billion. Management flagged accelerated erosion for Prolia and XGEVA from biosimilars, continued Enbrel and RAVICTI erosion, and a Q1 seasonal pattern. A significant new risk emerged after the period: on January 16, 2026, the FDA asked ChemoCentryx to withdraw TAVNEOS from the U.S. market, which Amgen declined to do on January 28, 2026, and the matter remains under review. Investors should weigh the strong growth in newer products such as Repatha, Tezspire, and Uplizna against pricing pressure, biosimilar competition, rising R&D spend, and the TAVNEOS regulatory overhang.

Feb 3, 2026 8-K

AMGEN INC 8-K Report, Agreement Terminated (Jan 30, 2026)

Amgen Inc. (AMGN) announced on January 30, 2026, the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., originally dated June 1, 2021. This termination is set to become effective upon receiving the necessary regulatory approvals, signaling a potential shift in Amgen's strategic partnerships and pipeline development. While the specific reasons for termination and the financial implications are not detailed in this filing, investors should monitor future communications for updates on how this development might impact Amgen's ongoing research and development efforts, particularly concerning any products or technologies covered under the terminated agreement. The agreement with Kyowa Kirin, if significant, could have implications for revenue streams, cost-sharing, or market access for certain therapeutic areas.

Jan 30, 2026 10-Q

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2025

Amgen Inc. reported strong financial performance for the third quarter and first nine months of 2025, with total revenues increasing by 12% and 11% year-over-year, respectively, driven primarily by robust volume growth across its key products. Net income saw significant increases, up 14% for the quarter and a substantial 84% for the nine-month period, leading to a corresponding surge in diluted Earnings Per Share (EPS). The company demonstrated effective cost management, with operating expenses growing at a slower pace than revenues. Strategic investments in late-stage clinical programs continue, supported by strong operational cash flow generation. The company's balance sheet remains solid, though cash and cash equivalents decreased slightly from year-end 2024, largely due to significant debt repayment and dividend payments. Amgen continues to manage its debt effectively, reducing its overall debt principal. The company also highlighted ongoing legal matters, particularly the significant U.S. Tax Court case, which, while expected to be resolved no earlier than the second half of 2026, continues to be a point of attention. Despite potential regulatory headwinds and ongoing litigation, Amgen's operational performance and strategic investments indicate a positive outlook for future growth.

Nov 5, 2025 8-K

AMGEN INC 8-K Report, Financial Results (Nov 4, 2025)

Amgen's third-quarter 2025 results show a mixed picture: top-line strength paired with a sharp GAAP earnings hit from a $400 million Otezla intangible asset impairment. Total revenues rose 12% to $9.6 billion, driven by 14% volume growth in product sales, and sixteen products grew at double-digit rates, including Repatha (+40%), EVENITY (+36%), TEZSPIRE (+40%), and BLINCYTO (+20%). GAAP EPS rose 14% to $5.93 from $5.22, but non-GAAP EPS grew only 1% to $5.64 as non-GAAP operating margin fell 2.5 points to 47.1%, reflecting a 31% increase in R&D spend tied to late-stage programs such as MariTide, where six global Phase 3 studies are underway. Enbrel sales fell 30% on Medicare Part D redesign and U.S. net price pressure, a headwind that is likely to persist. Cash generation was the quarter's clear bright spot. Free cash flow reached $4.2 billion versus $3.3 billion a year earlier, helped by working capital timing and lower interest payments. Amgen retired $1.6 billion of debt in the quarter and $6.0 billion year to date, reducing total debt to $54.6 billion from $60.1 billion at year-end 2024. No shares were repurchased in Q3, and the company paid a $2.38 quarterly dividend, up 6% year over year. Management kept full-year 2025 guidance essentially intact, with revenue of $35.8–36.6 billion and non-GAAP EPS of $20.60–21.40, though the GAAP range was not changed to reflect future impairments or equity gains. Pipeline news was the other key focus. Repatha's Phase 3 VESALIUS-CV trial met its dual primary endpoints in patients without prior heart attack or stroke, a potentially significant label expansion to be presented at AHA on November 8. Upcoming catalysts include FDA decisions on UPLIZNA for generalized myasthenia gravis (PDUFA December 14, 2025) and IMDELLTRA for relapsed ES-SCLC (PDUFA December 18, 2025), along with MariTide Phase 2 data in Q4 2025. Investors should weigh strong volume momentum and the late-stage pipeline against margin compression, Enbrel erosion, and the continuing risk of further intangible asset impairments.

Nov 4, 2025 10-Q

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2025

Amgen Inc. reported robust top-line growth for the second quarter and first half of 2025, with total revenues increasing by 9% and 10% respectively compared to the prior year periods. This growth was primarily driven by strong volume increases across key products, notably Repatha, EVENITY, BLINCYTO, and TEZSPIRE, which collectively offset modest net selling price declines. The company demonstrated significant profitability improvements, with net income soaring by 92% and 92% for the respective periods, and diluted EPS more than doubling year-over-year. This performance was supported by improved cost of sales as a percentage of revenue and well-managed selling, general, and administrative expenses, although R&D investments saw an increase. Despite the strong operational performance, investors should note the ongoing legal challenges, particularly the significant tax dispute with the IRS concerning past tax years, which continues through the judicial process. The company also faces ongoing patent litigations related to its key products like Repatha and Prolia/XGEVA, with several new biosimilar infringement lawsuits filed. While Amgen has a strong liquidity position with substantial cash and cash equivalents, its balance sheet reflects a notable decrease in cash from the prior year-end, largely due to significant debt repayments and dividend distributions. The company reiterated its commitment to capital allocation through debt reduction, dividends, and stock repurchases.

Aug 6, 2025 8-K

AMGEN INC 8-K Report, Financial Results (Aug 5, 2025)

Amgen (AMGN) reported Q2 2025 results that beat on the top and bottom line, with total revenues up 9% to $9.2 billion, driven by 13% volume growth partially offset by 3% lower net selling price. Product sales reached $8.77 billion, and 15 products grew at least double digits, led by Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA and TAVNEOS. GAAP diluted EPS rose 92% to $2.65 from $1.38, and non-GAAP EPS rose 21% to $6.02 from $4.97. The GAAP improvement is flattered by lower acquisition-related amortization tied to Horizon and by a $591 million unrealized loss on equity investments, which is excluded from non-GAAP results, so investors should weigh the two measures together. Profitability and cash generation were mixed. Non-GAAP operating margin expanded 0.7 points to 48.9%, but free cash flow fell to $1.9 billion from $2.2 billion, reflecting 2024 tax payments shifted into 2025 and higher capex. Operating cash flow was $2.3 billion. Debt was reduced by $1.4 billion in the quarter and $4.3 billion year to date, bringing debt outstanding to $56.2 billion against $8.0 billion of cash. No shares were repurchased in the quarter. Pricing pressure is visible in Enbrel, which fell 34% on 340B mix and Medicare Part D redesign, and in Prolia and XGEVA, which face biosimilar erosion in the second half. Management reaffirmed or set 2025 guidance of $35.0–36.0 billion in revenue, GAAP EPS of $10.97–12.11, and non-GAAP EPS of $20.20–21.30. The guidance excludes unimplemented tariffs and pricing actions. The pipeline news flow is heavy in the second half, with the MariTide Part 2 and T2D readouts expected in Q4 2025, VESALIUS-CV for Repatha in H2 2025, the UPLIZNA PDUFA date on December 14, 2025, and the TEZSPIRE CRSwNP PDUFA date on October 19, 2025.

Aug 5, 2025 8-K

AMGEN INC 8-K Report, Shareholder Vote Results (May 27, 2025)

Amgen Inc. (AMGN) filed an 8-K report on May 27, 2025, detailing the outcomes of its annual meeting of stockholders held on May 22, 2025. The report primarily covers the election of directors, advisory votes on executive compensation, and the ratification of independent auditors. All 12 director nominees were overwhelmingly elected to serve a one-year term. Additionally, shareholders provided an advisory vote to approve executive compensation, which passed with a significant majority. Furthermore, the company's selection of Ernst & Young LLP as its independent registered public accountants for the fiscal year ending December 31, 2025, was ratified by stockholders. The voting results across all presented proposals indicate strong shareholder support for the company's governance and financial oversight practices. No other business was presented or voted upon during the meeting.

May 27, 2025 10-Q

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2025

Amgen Inc. reported a significant turnaround in the first quarter of 2025, with net income swinging from a loss of $113 million in Q1 2024 to a profit of $1.73 billion in Q1 2025. This substantial improvement was driven by a robust increase in total revenues, which grew by 9% year-over-year to $8.15 billion, primarily fueled by an 11% rise in product sales to $7.87 billion. The company's operating income also saw a healthy increase of 19% to $1.18 billion, reflecting effective cost management despite a notable $800 million impairment charge related to Otezla. The balance sheet shows a decrease in cash and cash equivalents to $8.81 billion from $11.97 billion, alongside a reduction in total debt. The company continues to prioritize shareholder returns, declaring a quarterly dividend of $2.38 per share, underscoring its commitment to financial health and shareholder value. Investors should note the ongoing legal proceedings, particularly the significant U.S. tax litigation, which remains a key area of focus, although a decision is not expected until the second half of 2026.

May 2, 2025 8-K

AMGEN INC 8-K Report, Financial Results (May 1, 2025)

Amgen reported first quarter 2025 results on May 1, 2025, with total revenues up 9% to $8.1 billion and product sales up 11% to $7.9 billion, driven by 14% volume growth partially offset by 6% lower net selling price. U.S. product sales grew 14%. Fourteen products delivered at least double-digit growth, including Repatha, BLINCYTO, TEZSPIRE, EVENITY, TAVNEOS and UPLIZNA, and the new launch IMDELLTRA generated $81 million in its first full quarter. Non-GAAP EPS rose 24% to $4.90 from $3.96, and non-GAAP operating margin expanded 2.5 points to 45.7%. GAAP diluted EPS of $3.20 was inflated by a $1.29 billion net gain on the BeiGene equity stake, which was partly offset by an $800 million non-cash impairment of the Otezla intangible asset. Cash generation and balance sheet items were mixed. Free cash flow was $1.0 billion versus $0.5 billion a year earlier, though the prior-year comparison was depressed by an $800 million tax deposit. Amgen reduced principal debt by $2.8 billion, ending the quarter with $57.4 billion in debt and $8.8 billion in cash. No shares were repurchased in the quarter, and the dividend was raised 6%. Management reiterated its 2025 guidance of $34.3 to $35.7 billion in revenue and non-GAAP EPS of $20.00 to $21.20, while noting that the outlook excludes possible future tariffs. For investors, the key watch items are the sustainability of volume-led growth as net pricing erodes, the competitive pressure from biosimilars on Prolia, XGEVA and Enbrel in the second half of 2025, and the pipeline catalysts expected in H2 2025, including MariTide Phase 2 data, the VESALIUS-CV outcomes readout and rocatinlimab maintenance and adolescent data. Because GAAP earnings are heavily affected by mark-to-market equity gains and acquisition amortization, the non-GAAP figures are a better gauge of underlying operating performance, though GAAP earnings guidance also carries a wide range.

May 1, 2025 10-K

AMGEN INC Annual Report, Year Ended Dec 31, 2024

Amgen's FY2024 10-K (filed February 14, 2025) shows a company whose top line grew strongly but whose profitability fell sharply. Total revenues rose 19% to $33.4 billion, driven by product sales of $32.0 billion, with volume growth of 23% offsetting a 2% decline in net selling price. The Horizon Therapeutics acquisition (closed October 2023) contributed $4.2 billion of product sales in 2024, and new launches such as TEZSPIRE, BLINCYTO, TEPEZZA, and Repatha grew rapidly. However, GAAP net income fell 39% to $4.1 billion and diluted EPS fell to $7.56 from $12.49, pressured by higher cost of sales (38.5% of revenue, up from 30.0%) driven by amortization of Horizon intangibles and inventory step-up, along with higher interest expense ($3.2 billion) and unrealized losses on equity investments. The outlook carries clear headwinds. Prolia and XGEVA face biosimilar competition after their RANKL patents expired in February 2025 in the U.S., and ENBREL's Medicare price set by CMS takes effect in 2026, with Otezla selected for price setting in 2027. Management also flags continued payer consolidation, 340B expansion, and state-level PDAB actions as pressures on net pricing. Balance-sheet leverage remains significant, with roughly $60.1 billion of total debt against $5.9 billion of stockholders' equity, though operating cash flow of $11.5 billion and a $2.38 quarterly dividend (up 6%) signal continued capacity to service obligations. Pipeline catalysts include MariTide (obesity, up to ~20% weight loss at 52 weeks in Phase 2), UPLIZNA (IgG4-RD PDUFA April 3, 2025), and rocatinlimab in atopic dermatitis. Material legal and tax risks remain unresolved. The IRS transfer-pricing dispute covering 2010–2015 seeks roughly $3.6 billion plus interest for 2010–2012 and $5.1 billion plus about $2.0 billion in penalties for 2013–2015, with a Tax Court decision not expected before 2026. Several biosimilar patent suits over denosumab and aflibercept are ongoing, and securities and derivative litigation tied to the tax disclosures continues.

Feb 14, 2025 8-K

AMGEN INC 8-K Report, Financial Results (Feb 4, 2025)

Amgen reported fourth-quarter and full-year 2024 results that combined strong top-line growth with a sharp GAAP earnings decline. Q4 total revenues rose 11% to $9.1 billion and full-year revenues rose 19% to $33.4 billion, driven by volume growth and the Horizon Therapeutics acquisition. Excluding Horizon, full-year product sales grew 7%. Non-GAAP EPS grew 13% in Q4 to $5.31 and 6% for the full year to $19.84, while GAAP EPS fell 39% for the year to $7.56, mainly due to Horizon-related amortization, higher operating expenses, and mark-to-market losses on equity investments, primarily BeiGene. Cash generation was a clear highlight. Free cash flow reached a record $4.4 billion in Q4 and $10.4 billion for the full year, up from $7.4 billion in 2023, helped partly by working capital timing. Amgen reduced principal debt by $4.5 billion in 2024, ending the year with $60.1 billion of debt and approximately 4.5x debt leverage on EBITDA. Management guided 2025 total revenues to $34.3–35.7 billion and non-GAAP EPS to $20.00–21.20, with GAAP EPS of $10.89–12.14. Investors should watch several headwinds: Prolia and Xgeva biosimilar erosion expected in 2025, continued net price declines for Enbrel and Repatha, high acquisition-related amortization depressing GAAP margins, and a large leverage load. Key pipeline catalysts include the UPLIZNA PDUFA date of April 3, 2025, MariTide Phase 2 Part 2 and diabetes data in H2 2025, the VESALIUS-CV outcomes readout in H2 2025, and several rocatinlimab Phase 3 readouts in H1 2025.

Feb 4, 2025 10-Q

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2024

Amgen Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $8.5 billion, up 23% year-over-year. This growth was primarily driven by a substantial 24% increase in total product sales, largely attributable to the successful integration of products acquired from Horizon Therapeutics. Key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE showed strong volume growth. Despite the revenue surge, net income saw a notable 64% increase to $2.83 billion, with diluted EPS rising to $5.22, reflecting improved operational efficiency and strategic asset contributions. However, operating expenses also grew significantly, up 32% in the quarter, largely due to higher amortization related to acquisition-related assets and increased R&D and SG&A spending. The company also reported a decrease in cash and cash equivalents to $9.0 billion from $10.9 billion at the end of the prior year, primarily due to debt repayments and dividend payments, though the company maintains ample liquidity. Investors should note the ongoing substantial legal and tax contingencies, particularly the IRS tax dispute, which continue to pose potential risks despite Amgen's belief in its strong legal standing.

Oct 31, 2024 8-K

AMGEN INC 8-K Report, Financial Results (Oct 30, 2024)

Amgen's third quarter 2024 results (reported October 30, 2024) showed strong top-line momentum and a sharp rise in GAAP earnings, but the quality of the GAAP profit picture is distorted by non-cash items. Total revenues rose 23% to $8.5 billion, and product sales grew 24% to $8.15 billion. Excluding the Horizon Therapeutics acquisition, product sales grew 8%, with volume up 12%, so the underlying organic growth is more modest than the headline suggests. Ten products posted at least double-digit growth, and rare disease sales reached $1.2 billion, led by TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS. GAAP diluted EPS rose 62% to $5.22, but this was driven mainly by a $1.6 billion mark-to-market gain on the BeiGene equity stake rather than operating performance. GAAP operating income was roughly flat at $2.0 billion, and GAAP operating margin fell 5.8 points to 25.1%, reflecting heavy Horizon-related amortization. Non-GAAP EPS rose 13% to $5.58, and non-GAAP operating margin of 49.6% declined 2.4 points, as incremental Horizon expenses and higher interest expense absorbed much of the revenue gain. Investors should focus on non-GAAP metrics and the free cash flow of $3.3 billion as the cleaner read on the business. Balance sheet deleveraging continued, with $2.5 billion of principal debt repaid in the quarter and $4.5 billion year-to-date, bringing debt outstanding to $60.4 billion against $9.0 billion of cash and investments. The company raised its full-year 2024 guidance: revenues of $33.0–33.8 billion, non-GAAP EPS of $19.20–$20.00, and GAAP EPS of $8.71–$9.56. Pipeline updates included positive Phase 3 HORIZON data for rocatinlimab in atopic dermatitis, an FDA Breakthrough Therapy Designation for UPLIZNA in IgG4-related disease, and continued Phase 3 development of MariTide for obesity, with Phase 2 topline data expected in late 2024.

Oct 30, 2024 10-Q

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2024

Amgen Inc. reported a notable increase in total revenues for the second quarter of 2024, reaching $8.4 billion, a 20% rise compared to the same period in the prior year. This growth was primarily driven by a significant 20% increase in product sales, largely attributable to the successful integration of Horizon Therapeutics and strong volume growth across key products. Despite the top-line expansion, operating income and net income experienced a decline due to a substantial increase in operating expenses, primarily driven by higher amortization related to the Horizon acquisition and increased R&D and SG&A expenses. Diluted EPS saw a corresponding decrease. The company's balance sheet shows a decrease in cash and cash equivalents to $9.3 billion from $10.9 billion at the end of 2023, alongside a reduction in total assets and stockholders' equity. Long-term debt also decreased. Amgen continued its commitment to capital allocation through dividend payments, though no shares were repurchased during the first half of 2024. The company remains focused on investing in innovation and managing its debt.

Aug 7, 2024 8-K

AMGEN INC 8-K Report, Financial Results (Aug 6, 2024)

Amgen's Q2 2024 results (filed August 6, 2024) showed strong top-line growth but a sharply lower GAAP profit picture, driven primarily by the Horizon Therapeutics acquisition. Total revenues rose 20% to $8.4 billion, with product sales up 20% to $8.0 billion. Excluding Horizon, product sales grew 5%, with volume growth of 10%. Growth was led by newer launches and franchises such as TEZSPIRE, EVENITY, Repatha, and TEPEZZA, while Enbrel, Otezla, and the established biologics declined. Twelve products grew at least double digits in the quarter. Profitability diverged sharply between GAAP and non-GAAP measures. GAAP diluted EPS fell 46% to $1.38 from $2.57, and GAAP operating margin dropped 16.5 points to 23.7%, largely because of roughly $1.8 billion of acquisition-related amortization and inventory step-up charges in cost of sales. Non-GAAP EPS was nearly flat at $4.97 versus $5.00, and non-GAAP operating margin declined 4.4 points to 48.2%, reflecting incremental Horizon operating costs and higher interest expense. Investors should weigh the non-GAAP figures against the large, recurring noncash amortization that the company excludes. Cash generation and balance sheet were mixed. Free cash flow fell to $2.2 billion from $3.8 billion, mainly because federal tax payments shifted from Q4 2023 into Q2 2024, so the decline is largely timing. Management reduced debt by $1.4 billion in the quarter and $2.0 billion year to date, and reaffirmed its target of more than $10 billion of debt reduction by the end of 2025. Total debt remained high at $62.6 billion against $9.3 billion of cash and investments. Full-year 2024 guidance was updated, with revenue of $32.8–33.8 billion and non-GAAP EPS of $19.10–20.10.

Aug 6, 2024 8-K

AMGEN INC 8-K Report, Executive Changes (Jun 3, 2024)

This 8-K filing from Amgen Inc. (AMGN) details the outcomes of its 2024 Annual Meeting of Stockholders held on May 31, 2024. The most significant information for investors pertains to the approval of the "Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan." This plan, now approved by stockholders, increases the number of shares available for issuance by over 31 million, clarifies dividend equivalent payouts, and incorporates updated change of control provisions to ensure unassumed awards will fully vest. Additionally, the filing confirms the election of all 12 director nominees for one-year terms and the advisory approval of executive compensation, indicating continued shareholder confidence in the current leadership and compensation structure. The ratification of Ernst & Young LLP as the independent registered public accountants for fiscal year 2024 also provides assurance regarding the company's financial reporting oversight. The appointment of Dr. Mary E. Klotman to the Corporate Responsibility and Compliance Committee and the Governance and Nominating Committee is a minor governance update. Overall, the filing reflects routine but important corporate governance actions, with the equity incentive plan amendment being the primary item of note for its potential impact on future equity-based compensation and share dilution.

Jun 3, 2024 10-Q

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2024

Amgen Inc. reported a net loss of $113 million, or $(0.21) per share, for the first quarter of 2024, a significant shift from the $2.84 billion net income reported in the same period last year. This change was largely attributed to substantial non-cash charges, including unrealized losses on strategic equity investments and increased amortization and acquisition-related expenses stemming from the recent Horizon Therapeutics acquisition. Despite the net loss, total revenues grew by 22% year-over-year to $7.45 billion, driven by a 22% increase in product sales to $7.12 billion. The growth in product sales was primarily fueled by volume increases, with significant contributions from newly acquired Horizon products like TEPEZZA and KRYSTEXXA. Operationally, the company saw robust growth in key products such as Repatha (33% increase) and TEZSPIRE (80% increase), alongside contributions from the newly acquired Horizon portfolio. However, operating expenses surged by 54%, largely due to the impact of the Horizon acquisition, including higher amortization and acquisition-related costs, alongside increased R&D and SG&A expenses. The company also continues to navigate complex legal and tax matters, including an ongoing IRS tax dispute with potentially significant financial implications. Amgen's balance sheet remains solid, with substantial cash and cash equivalents, though debt levels remain elevated following the acquisition.

May 3, 2024 8-K

AMGEN INC 8-K Report, Financial Results (May 2, 2024)

Amgen's first quarter 2024 results show strong top-line momentum but a sharply weaker GAAP profile. Total revenues rose 22% to $7.4 billion and product sales grew 22% on 25% volume growth, with the Horizon Therapeutics acquisition contributing $914 million. Excluding Horizon, product sales grew 6%, driven by 9% volume growth. Key growth drivers included Repatha (+33%), TEZSPIRE (+80%), EVENITY (+35%) and BLINCYTO (+26%), while Enbrel, Nplate, Neulasta and EPOGEN declined. Profitability was significantly pressured by acquisition accounting and the Horizon integration. GAAP EPS was a loss of $0.21 versus $5.28 a year earlier, driven by a $510 million mark-to-market loss on the BeiGene equity stake, higher amortization of Horizon-acquired intangibles, and incremental Horizon operating costs. GAAP operating income fell from $1.9 billion to $1.0 billion. On a non-GAAP basis, EPS declined 1% to $3.96 and non-GAAP operating margin fell 5.1 points to 43.2%, reflecting higher operating and interest expenses. Free cash flow was $0.5 billion versus $0.7 billion, reflecting an $800 million tax deposit. Management raised full-year guidance for total revenues ($32.5-33.8 billion) and non-GAAP EPS ($19.00-20.20), while GAAP EPS guidance is $7.15-8.40. For investors, the central question is whether Horizon-driven revenue growth and the pipeline (including tarlatamab and MariTide, with PDUFA dates in June 2024) can offset margin compression, rising debt of $64.0 billion, and continued erosion in legacy products.

May 2, 2024 10-K

AMGEN INC Annual Report, Year Ended Dec 31, 2023

Amgen's FY2023 10-K shows a transformative but leveraged year. Total revenues rose 7% to $28.2 billion and product sales grew 9% to $26.9 billion, driven by volume growth in Repatha, TEZSPIRE, EVENITY, Prolia and BLINCYTO, plus $954 million of product sales from Horizon after its October 6, 2023 closing. GAAP operating income fell 17% to $7.9 billion, however, because of higher cost of sales from Horizon-related amortization, a $783 million AMG 340 impairment, and higher SG&A. Net income rose 3% to $6.7 billion and diluted EPS reached $12.49. Operating cash flow was $8.5 billion, down from $9.7 billion, reflecting Horizon transaction and integration payments. The key investor issue is the balance sheet. The $27.8 billion Horizon acquisition was funded mainly by $24 billion of senior notes and a $4 billion term loan, pushing long-term debt to $63.2 billion from $37.4 billion. Stockholders' equity was only $6.2 billion, and the company has an accumulated deficit. Management stated that S&P, Moody's and Fitch ratings were BBB+, Baa1 and BBB, all still investment grade, but the filing acknowledges downgrades. Management plans to reduce leverage before returning to debt markets, and it paused share buybacks in 2023 while keeping the quarterly dividend, raised 10% to $2.13 per share for 2023 and to $2.25 for Q1 2024. The main medium-term risks are concentrated. Three wholesalers account for 79% of gross revenue, and the top PBMs and insurers control about 92% of prescriptions. The IRA's Medicare price-setting begins in 2026 with ENBREL selected, and biosimilar competition is intensifying for ENBREL, EPOGEN, Neulasta and others. The company also faces a large IRS tax dispute covering 2010–2015, with Tax Court trial set for November 2024 and $3.6 billion plus $5.1 billion of asserted federal tax and about $2.0 billion of penalties. Pipeline catalysts include the tarlatamab BLA decision (PDUFA June 12, 2024), while the LUMAKRAS full-approval application received a Complete Response Letter.

Feb 14, 2024 8-K

AMGEN INC 8-K Report, Financial Results (Feb 6, 2024)

Amgen reported fourth-quarter and full-year 2023 results on February 6, 2024, with the headline story being a sharp GAAP earnings decline in Q4 driven by acquisition accounting from the Horizon Therapeutics deal, offset by strong underlying product growth. Q4 total revenues rose 20% to $8.2 billion, with product sales up 20% on 23% volume growth. Horizon contributed $954 million of sales from October 6 to December 31, and excluding Horizon, product sales grew 5%. Q4 GAAP diluted EPS fell 53% to $1.42 from $3.00, while non-GAAP EPS rose 15% to $4.71. For the full year, GAAP EPS rose 3% to $12.49 (helped by a $1.5 billion equity gain on BeiGene), while non-GAAP EPS rose 5% to $18.65. The balance sheet and cash flow picture warrants attention. Total debt climbed to $64.6 billion from $38.9 billion, and leverage stood at about 4.4 times EBITDA. Full-year free cash flow fell to $7.4 billion from $8.8 billion, driven by Horizon transaction costs and higher repatriation tax payments. Q4 free cash flow was only $0.3 billion. Management guided 2024 total revenues to $32.4 to $33.8 billion, non-GAAP EPS to $18.90 to $20.30, and GAAP EPS to $8.42 to $9.87, and repurchases are capped at $500 million. Investors should weigh the Horizon-driven growth and pipeline catalysts, including tarlatamab and BLINCYTO PDUFA dates in June 2024, against the elevated leverage and the substantial GAAP-to-non-GAAP gap. The filing itself is a routine Item 2.02 disclosure furnishing the earnings release as Exhibit 99.1, with non-GAAP reconciliations provided. It does not contain new strategic announcements beyond what is in the release.

Feb 6, 2024 8-K

AMGEN INC 8-K Report, Executive Changes (Dec 14, 2023)

Amgen (AMGN) filed an 8-K on December 14, 2023 disclosing two senior R&D leadership changes, effective December 18, 2023. James Bradner, M.D., former President of the Novartis Institutes for BioMedical Research and a member of the Novartis Executive Committee, joins as Executive Vice President, Research and Development, and Chief Scientific Officer, succeeding David M. Reese, M.D., who moves to a newly created position of Executive Vice President and Chief Technology Officer. Reese will lead accelerated use of technology and artificial intelligence across the company, building on his role as architect of Amgen's AI initiatives. Both executives report to Chairman and CEO Robert A. Bradway. For investors, the filing is primarily a governance and strategic signal rather than a financial event. The filing contains no financial results, guidance changes, or quantified cost or compensation terms, so it does not by itself alter near-term earnings expectations. The key takeaway is that Amgen is formally separating scientific leadership of its pipeline from technology and AI strategy, and bringing in an external R&D head with a large-pharma background to oversee the pipeline across oncology, inflammation, general medicine, rare disease, and biosimilars. The appointments matter most for the long-term pipeline. Investors should watch whether Bradner's leadership produces pipeline milestones and whether the new CTO role yields measurable productivity or R&D efficiency gains. The filing does not disclose compensation arrangements for either executive, which would appear in a subsequent filing if material.

Dec 14, 2023 10-Q

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2023

Amgen Inc. reported total revenues of $6.9 billion for the third quarter of 2023, a 4% increase compared to the same period last year, driven by a 5% rise in product sales to $6.5 billion. For the nine-month period, total revenues grew by 3% to $19.99 billion. Net income for the third quarter was $1.73 billion, a decrease of 19% year-over-year, resulting in diluted EPS of $3.22. However, for the nine-month period, net income surged by 21% to $5.95 billion, with diluted EPS of $11.06, demonstrating strong performance over the year-to-date. A significant event during the quarter was the completion of the acquisition of Horizon Therapeutics plc on October 6, 2023, for approximately $27.8 billion. This strategic move is expected to bolster Amgen's inflammation portfolio with key treatments for rare inflammatory diseases. The company also made progress in its pipeline, announcing positive Phase 2 data for tarlatamab in small cell lung cancer and positive Phase 3 data for LUMAKRAS/LUMYKRAS in colorectal cancer.

Oct 31, 2023 8-K

AMGEN INC 8-K Report, Financial Results (Oct 31, 2023)

Amgen's third-quarter 2023 results, reported October 31, 2023, showed mixed headline performance. Total revenues rose 4% year-over-year to $6.9 billion, with product sales up 5% on 11% volume growth, partially offset by 3% lower net selling price and 3% unfavorable changes to sales deductions. Growth was led by Repatha (+31%), EVENITY (+53%), BLINCYTO (+55%), TEZSPIRE and Nplate (+45%). Offsetting this, established products fell 30%, Enbrel declined 6%, Otezla declined 10%, and KANJINTI fell 72%. GAAP EPS fell 19% to $3.22 from $3.98, driven primarily by a roughly $650 million net impairment charge tied to the decision to discontinue AMG 340. Non-GAAP EPS rose 6% to $4.96 from $4.70, and non-GAAP operating margin held near 52%. Free cash flow was $2.5 billion versus $2.8 billion a year earlier. The company reported $60.5 billion of debt against $34.7 billion of cash and investments, reflecting financing for the Horizon Therapeutics acquisition, which closed on October 6, 2023 and will be consolidated beginning in Q4 2023. Management raised its full-year 2023 guidance: total revenues of $28.0 to $28.4 billion, GAAP EPS of $11.23 to $12.73, and non-GAAP EPS of $18.20 to $18.80. Investors should weigh the strong growth in newer launches and the pipeline progress against sharp erosion in the mature biosimilar and established-product portfolio, the higher interest burden from acquisition debt, and the significant GAAP-to-non-GAAP gap driven by acquisition amortization.

Oct 31, 2023 8-K

AMGEN INC 8-K Report, Acquisition Completed (Oct 6, 2023)

On October 6, 2023, Amgen completed its acquisition of Horizon Therapeutics plc, which became a wholly owned subsidiary following a court-sanctioned Irish scheme of arrangement. Horizon shareholders received $116.50 in cash per share, with Amgen paying approximately $26.7 billion to shareholders of record as of the Scheme Record Time. Amgen's press release cites a transaction equity value of approximately $27.8 billion, which includes Horizon equity awards and the value of assumed obligations. Horizon's equity awards were largely converted into Amgen restricted stock units, while non-employee director and former service-provider awards were cashed out. To fund the deal, Amgen borrowed $4 billion under the Term Loan Credit Agreement entered into in December 2022, with the remainder financed through other sources disclosed in prior filings. Management emphasized that the acquisition adds first-in-class rare inflammatory disease medicines, including TEPEZZA, KRYSTEXXA and UPLIZNA, and expects it to be accretive to non-GAAP earnings per share starting in 2024. Amgen also stated it will provide updated FY 2023 guidance on its third quarter earnings call, which will be the first formal read-through of how the deal affects near-term results. Investors should weigh the strategic benefits against the risks highlighted in the filing, including integration challenges, the possibility that synergies take longer to realize than expected, and the added debt load. The company also reaffirmed its commitment to an investment grade credit rating and to ongoing R&D investment, and the filing notes that Horizon shares were delisted from Nasdaq and will be deregistered under the Exchange Act.

Oct 6, 2023 8-K

AMGEN INC 8-K Report, Corporate Update (Oct 5, 2023)

Amgen Inc. announced a significant development in its acquisition of Horizon Therapeutics plc. On October 5, 2023, the High Court of Ireland sanctioned the scheme of arrangement for the acquisition. This regulatory approval is a critical step towards the completion of the transaction, which was initially announced on December 11, 2022. While the court's sanction is a major milestone, the acquisition is not yet fully complete. Amgen still needs to deliver a copy of the court order to the Registrar of Companies in Ireland. Investors should monitor this final procedural step, as it will pave the way for the official closing of the transaction and the integration of Horizon Therapeutics into Amgen's operations. This acquisition is expected to bolster Amgen's product portfolio and market presence.

Oct 5, 2023 8-K

AMGEN INC 8-K Report, Corporate Update (Sep 12, 2023)

Amgen Inc. (AMGN) has filed an 8-K report on September 11, 2023, providing an update on its proposed acquisition of Horizon Therapeutics plc. The key takeaway for investors is that the exclusivity period for the transaction has been extended. The "First Extended End Date" under the Transaction Agreement has been automatically pushed to the "Second Extended End Date," which is December 12, 2023. This extension suggests that both parties are continuing to work towards closing the deal, but also indicates that the process is taking longer than initially anticipated.

Sep 12, 2023 8-K

AMGEN INC 8-K Report, Corporate Update (Sep 5, 2023)

Amgen Inc. (AMGN) has provided an update on its previously announced acquisition of Horizon Therapeutics plc. The company has successfully resolved its legal challenge with the Federal Trade Commission (FTC) regarding the acquisition. The FTC's administrative lawsuit has been dismissed following a stipulated order agreement between Amgen, Horizon, and the FTC, which was approved by the U.S. District Court for the Northern District of Illinois. This effectively ends the FTC's legal opposition to the deal. Furthermore, the Irish High Court has scheduled a hearing for October 5, 2023, to review Horizon's application for sanctioning the proposed scheme of arrangement under Irish law. This is a crucial step in finalizing the acquisition under Irish corporate regulations. The resolution with the FTC and the upcoming Irish court hearing are positive developments, indicating progress towards the completion of Amgen's acquisition of Horizon.

Sep 5, 2023 8-K

AMGEN INC 8-K Report, Regulation FD Disclosure (Sep 1, 2023)

Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced on September 1, 2023 that Amgen entered into a consent order agreement with the U.S. Federal Trade Commission that resolves the pending FTC administrative lawsuit challenging the Horizon acquisition. This is a significant de-risking step: the FTC litigation was the main regulatory obstacle to closing the transaction, and the resolution clears the path for the parties to complete the remaining procedural steps. Under the consent order, the parties expect to jointly file stipulated orders in the U.S. District Court for the Northern District of Illinois to dismiss the preliminary injunction motion and dissolve the temporary restraining order. Amgen and Horizon also intend to quickly seek the final approvals required under Irish law. The companies state that the consent order reflects a narrow assurance that Amgen has no reason, ability or intention to bundle Horizon's TEPEZZA (teprotumumab-trbw) or KRYSTEXXA (pegloticase injection) with Amgen's products, and they expect this to have no impact on Amgen's business. The companies anticipate closing the acquisition in early Q4 2023. Investors should note that the release's forward-looking statements flag remaining risks, including whether and when the district court enters the order dissolving the TRO, whether and when an Irish High Court sanction hearing is scheduled, satisfaction of closing conditions, and the possibility of termination or additional legal proceedings. The filing itself does not disclose transaction price, financing details, or financial impact, so those must be sourced from other filings.

Sep 1, 2023 10-Q

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2023

Amgen Inc. reported solid financial results for the second quarter and first half of 2023, demonstrating revenue growth driven by key products like Prolia and Repatha. Total revenues for the quarter rose 6% to $6.99 billion, with product sales increasing by 6% to $6.68 billion. For the first six months, total revenues grew 2% to $13.09 billion, and product sales were up 4% to $12.53 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, translating to diluted EPS of $2.57, up 5%. The first half of the year saw a substantial 51% increase in net income to $4.22 billion, with diluted EPS soaring 53% to $7.86. This strong performance was bolstered by a significant increase in cash from operations and strategic debt issuances related to the proposed acquisition of Horizon Therapeutics, alongside a notable increase in long-term debt. The company continues to navigate potential regulatory challenges, particularly the FTC's lawsuit seeking to block the Horizon acquisition, with a preliminary injunction hearing scheduled. Amgen also remains engaged in ongoing patent litigation and tax disputes, though the company expresses confidence in its legal positions and financial resilience.

Aug 4, 2023 8-K

AMGEN INC 8-K Report, Executive Changes (Aug 4, 2023)

Amgen Inc. (AMGN) announced a key leadership transition in its finance department, effective August 14, 2023. Matthew C. Busch has been appointed as the new Vice President, Finance and Chief Accounting Officer (CAO), stepping into the role of principal accounting officer. This appointment is part of the company's leadership development initiatives, with the current CAO, Linda H. Louie, transitioning to Vice President, Finance, focusing on corporate financial planning and analysis. Mr. Busch has a long tenure at Amgen, having served in various finance and accounting roles since 2004, and most recently as Vice President, Finance. His compensation package for the CAO role includes a base salary of $450,000, an annual bonus target of 40% of his base salary, and an annual long-term incentive equity award valued at $500,000. This change appears to be a planned internal promotion aimed at fostering talent within the organization.

Aug 4, 2023 8-K

AMGEN INC 8-K Report, Financial Results (Aug 3, 2023)

Amgen reported a strong second quarter 2023, with total revenues up 6% to $7.0 billion and product sales up 6% to $6.7 billion, driven by 11% volume growth that was partly offset by 2% lower net selling price, 1% lower inventory and a 1% FX headwind. GAAP diluted EPS rose 5% to $2.57 and non-GAAP diluted EPS rose 8% to $5.00. Growth was led by Repatha, EVENITY, BLINCYTO, Prolia and TEZSPIRE, while biosimilars and established products such as MVASI, KANJINTI, Neulasta and EPOGEN declined on pricing and competition. Free cash flow was $3.8 billion, versus $1.7 billion a year earlier, helped by the timing of tax payments. The company raised its 2023 non-GAAP EPS guidance to $17.80-$18.80 and its GAAP EPS guidance to $14.30-$15.41, both excluding the pending Horizon Therapeutics acquisition, which management expects to close by mid-December 2023. Debt rose to $61.5 billion from $38.9 billion at year-end 2022, reflecting acquisition financing, and interest expense, net more than doubled year over year. Investors should weigh the strong cash generation and pipeline readouts against rising leverage, net price erosion in key franchises and the uncertainty around the Horizon deal, including the Federal Trade Commission litigation referenced in the forward-looking statements. Pipeline news was also significant. Phase 2 DeLLphi-301 data for tarlatamab in small cell lung cancer were positive, and the Phase 3 CodeBreaK 300 study of LUMAKRAS plus Vectibix in colorectal cancer met its primary endpoint. The LUMAKRAS NSCLC supplemental NDA carries a PDUFA date of December 24, 2023.

Aug 3, 2023 8-K

AMGEN INC 8-K Report, Corporate Update (Jun 5, 2023)

This 8-K filing from Amgen Inc. (AMGN) provides an update on the status of its proposed acquisition of Horizon Therapeutics plc. The primary focus is on the ongoing regulatory review by the U.S. Federal Trade Commission (FTC) and the legal proceedings stemming from the FTC's challenge to the acquisition. The filing details extensions to temporary restraining orders (TROs) that prevent Amgen from closing the deal until the court rules on the FTC's request for a preliminary injunction. Investors are informed that the court has scheduled an evidentiary hearing on the preliminary injunction for September 11, 2023. Based on this schedule, Amgen now anticipates the potential closing of the acquisition by mid-December, assuming the court denies the FTC's request. The company emphasizes that this timeline is contingent on the court's ruling and the satisfaction of other closing conditions.

Jun 5, 2023 8-K

AMGEN INC 8-K Report, Shareholder Vote Results (May 22, 2023)

Amgen Inc. (AMGN) filed an 8-K on May 22, 2023, detailing the results of its Annual Meeting of Stockholders held on May 19, 2023. The primary focus for investors is the overwhelmingly positive outcome of key shareholder votes, including the election of all 13 director nominees and the approval of executive compensation on an advisory basis. The company also ratified Ernst & Young LLP as its independent registered public accountants for the upcoming fiscal year. Significantly, shareholders voted overwhelmingly in favor of an annual advisory vote on executive compensation, aligning with the Board of Directors' recommendation. This indicates strong shareholder confidence in the company's governance and compensation practices. The consistent and high levels of support across all presented proposals suggest a stable and well-aligned shareholder base.

May 22, 2023 8-K

AMGEN INC 8-K Report, Corporate Update (May 18, 2023)

Amgen Inc. (AMGN) has filed an 8-K detailing an update regarding its proposed acquisition of Horizon Therapeutics plc. The U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block the acquisition, leading to a temporary restraining order (TRO) being issued by the court. This TRO prevents Amgen from closing the Horizon acquisition until at least September 15, 2023, or until the court makes a ruling on the FTC's request for a preliminary injunction. This development introduces significant uncertainty for investors regarding the completion of the Horizon acquisition, which was previously announced in December 2022. The legal challenge by the FTC is a critical hurdle, and the September 15th deadline set by the stipulated TRO provides a timeframe for further legal proceedings. Investors should monitor any updates on the court's decision regarding the preliminary injunction and Amgen's strategic responses.

May 18, 2023 8-K

AMGEN INC 8-K Report, Regulation FD Disclosure (May 16, 2023)

On May 16, 2023, Amgen disclosed that the U.S. Federal Trade Commission filed a complaint in the Northern District of Illinois seeking to enjoin Amgen's pending acquisition of Horizon Therapeutics plc, first agreed on December 11, 2022 under a Transaction Agreement with Amgen's subsidiary Pillartree Limited. The filing itself is a Regulation FD disclosure furnishing Amgen's press release responding to the action. The core investor issue is deal risk: the FTC's theory centers on possible future bundling (multi-product discounts) of Amgen and Horizon rare-disease medicines rather than on direct product overlap, which Amgen says does not exist. Amgen's response is combative but conditional. It states it remains committed to closing, argues the companies' medicines treat different diseases and patient populations, and notes it has already committed not to bundle the Horizon products that the FTC raised as concerns. Management also said it intends to work with the court on a schedule that would allow closing by mid-December 2023, which signals the expected litigation timeline and that the deal is not yet closed. For investors, the key takeaways are that closing is now subject to litigation outcome and timing, that the complaint creates uncertainty about deal completion and integration benefits, and that the filing's forward-looking risk language explicitly flags the possibility that Horizon synergies may take longer or prove harder to realize. The filing does not quantify financial exposure, termination fees, or the probability of success, so investors will need to monitor court filings and any further 8-K updates.

May 16, 2023 10-Q

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2023

Amgen Inc. reported total revenues of $6.105 billion for the first quarter of 2023, a slight decrease from $6.238 billion in the same period of 2022. Despite the revenue dip, net income saw a significant increase, soaring to $2.841 billion ($5.28 diluted EPS) from $1.476 billion ($2.68 diluted EPS) in the prior year. This substantial earnings growth was largely driven by a substantial "Other income (expense), net" of $2.064 billion, primarily attributed to a significant unrealized gain from revaluing their investment in BeiGene. The company's strategic debt issuances totaling $24.0 billion in March 2023 were to finance the proposed acquisition of Horizon Therapeutics, which remains subject to regulatory review. Product sales showed modest growth of 2% to $5.846 billion, bolstered by strong performances from Prolia, Repatha, Nplate, and EVENITY. However, Enbrel and Otezla experienced declines. Operating expenses increased by 12% due to higher costs of sales, R&D investments, and expenses related to a restructuring plan. The company ended the quarter with a robust cash position of $31.6 billion, with a significant portion earmarked for the Horizon acquisition.

Apr 28, 2023 8-K

AMGEN INC 8-K Report, Financial Results (Apr 27, 2023)

Amgen's first quarter 2023 results (reported April 27, 2023) show a mixed picture: total revenues fell 2% to $6.1 billion, as 14% volume growth and a 2% rise in product sales were offset by lower Other Revenue from a COVID-19 manufacturing collaboration, 5% lower net selling price, 3% unfavorable sales-deduction changes and 2% lower inventory levels. GAAP diluted EPS rose 97% to $5.28, but this was driven by a $1.85 billion mark-to-market gain on the BeiGene stake rather than operations. Non-GAAP diluted EPS fell 6% to $3.98, with non-GAAP operating margin down 6.5 points to 48.3% as R&D rose 12%. Investors should treat the GAAP improvement as non-recurring and focus on the underlying operating pressure. Cash generation weakened sharply. Free cash flow was $0.7 billion versus $2.0 billion a year earlier, reflecting timing of sales-incentive payments, lower operating income and higher capex for new North Carolina and Ohio facilities. Total debt rose to $61.6 billion from $38.9 billion at year-end 2022, following senior note issuances and bridge financing for the pending Horizon Therapeutics acquisition, which management expects to close in the first half of 2023. Share repurchases were zero in the quarter versus $6.3 billion a year earlier. Full-year 2023 guidance (excluding Horizon) was set at $26.2-27.3 billion in revenue and non-GAAP EPS of $17.60-18.70. Product-level performance was uneven. Growth drivers included EVENITY (+49%), AMJEVITA (+52%, partly inventory build), BLINCYTO (+41%), KYPROLIS (+25%), Repatha (+18%) and Nplate (+36%). Erosion was concentrated in Enbrel (-33%), Neulasta (-28%), Aimovig (-32%), KANJINTI (-51%) and MVASI (-17%), where biosimilar competition and pricing pressure are expected to continue. Otezla also declined 13% amid free-drug programs from new competitors. The filing notes the Horizon deal and the mix of growth versus biosimilar-driven erosion as the key items to monitor.

Apr 27, 2023 8-K

AMGEN INC 8-K Report, Material Agreement (Mar 9, 2023)

Amgen Inc. (AMGN) has announced a significant amendment and restatement of its revolving credit facility, increasing its total commitment to $4.0 billion. This facility, with an initial five-year term extendable by two additional one-year periods, is designed for general corporate purposes and serves as a liquidity backstop for its commercial paper program. The credit agreement includes provisions for an additional $1.25 billion increase at Amgen's request, subject to bank discretion and customary requirements. This strategic move enhances Amgen's financial flexibility and provides robust liquidity to support its operations and potential future needs. Furthermore, Amgen has fully terminated its previously established $28.5 billion bridge credit facility. This termination, effective March 9, 2023, follows the successful securing of substantial financing through senior notes, a term loan facility, and existing cash reserves. The company has determined that these combined liquidity sources are sufficient to finance the completion of its acquisition of Horizon Therapeutics plc, rendering the bridge facility unnecessary. The termination signifies a prudent management of its debt structure and a clear pathway to funding its strategic growth initiatives.

Mar 9, 2023 8-K

AMGEN INC 8-K Report, Material Agreement (Mar 2, 2023)

On March 2, 2023, Amgen issued $24.0 billion of senior unsecured notes in eight tranches maturing from 2025 to 2063, with coupons from 5.150% to 5.750%. Net proceeds were about $23.77 billion after underwriting discounts and offering expenses. Amgen plans to use the proceeds to fund its pending acquisition of Horizon Therapeutics plc under the transaction agreement signed December 11, 2022. The offering is not conditioned on the acquisition closing, so Amgen has committed to a financing that stands regardless of the deal's outcome. The main investor protection is a special mandatory redemption feature. If the acquisition does not close by the Special Mandatory Redemption End Date (the later of January 31, 2024 or any extension under the transaction agreement), the agreement is terminated, or Amgen notifies the trustee it will not pursue the deal, Amgen must redeem all series except the 2063 Notes at 101% of principal plus accrued interest. Holders also have a change-of-control put at 101% of principal plus accrued interest. The notes rank equally with Amgen's other senior unsecured debt but are effectively subordinated to subsidiary obligations and secured debt. The filing also reduces the $28.5 billion Bridge Credit Facility by the net proceeds from the notes, which lowers Amgen's reliance on bank bridge financing and replaces it with longer-dated fixed-rate debt. The result is a larger fixed-rate debt load and higher annual interest expense, weighed against a more predictable and less expensive refinancing path for the acquisition. Investors should watch whether the acquisition closes before the redemption deadline and how the added leverage affects Amgen's credit profile.

Mar 2, 2023 8-K

AMGEN INC 8-K Report, Material Agreement (Feb 16, 2023)

Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering completed on February 15, 2023. The company entered into an underwriting agreement to issue and sell a substantial aggregate principal amount of senior notes across various maturity dates, totaling approximately $23.4 billion. These new notes will rank equally with Amgen's other senior unsecured debt and will mature between 2025 and 2063, with coupon rates ranging from 5.150% to 5.750%. The proceeds from this offering are not explicitly stated in this filing but are typically used for general corporate purposes, potential acquisitions, or refinancing existing debt. Investors should note the closing date for this offering is expected to be March 2, 2023.

Feb 16, 2023